Lexeo Therapeutics (LXEO) Operating Leases (2022 - 2026)

Lexeo Therapeutics has reported Operating Leases for 5 years, with the latest figure at $4.5 million in Q1 2026.

• Quarterly Operating Leases fell 26.13% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 26.13% YoY) and the FY2025 annual result came in at $4.9 million, down 24.13% from the prior year.
• Operating Leases slipped to $4.5 million in Q1 2026 per LXEO's latest filing, from $4.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $9.0 million in Q4 2022 and troughed at $4.5 million in Q1 2026.
• A 5-year average of $6.6 million and a median of $6.6 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2026: Operating Leases declined 13.49% in 2023, then fell 26.13% in 2026.
• Over 5 years, Operating Leases stood at $9.0 million in 2022, then fell by 13.49% to $7.8 million in 2023, then declined by 17.33% to $6.4 million in 2024, then retreated by 24.13% to $4.9 million in 2025, then slipped by 8.44% to $4.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.5 million, $4.9 million, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.